Distal Hereditary Motor Neuronopathy, Autosomal Dominant (AD-dHMN) — Comprehensive Disease Characteristics Report

Target disease

Disease name: Distal hereditary motor neuronopathy / distal hereditary motor neuropathy, autosomal dominant (often abbreviated AD-dHMN) (xie2020geneticandclinical pages 1-2, frasquet2021distalhereditarymotor pages 1-2, bansagi2017clinicalandgenetic pages 58-62).
Category: Rare inherited lower motor neuron / motor-predominant peripheral neuropathy (“hereditary motor neuropathy”, HMN) (zambon2023earlyonsethereditary pages 1-2, frasquet2021distalhereditarymotor pages 1-2).
Synonyms and related terms: distal hereditary motor neuropathy (dHMN), hereditary motor neuropathy (HMN), distal spinal muscular atrophy (dSMA), “motor CMT2”/axonal Charcot–Marie–Tooth overlap spectrum (frasquet2021distalhereditarymotor pages 1-2, bansagi2017clinicalandgenetic pages 58-62, zambon2023earlyonsethereditary pages 1-1).

Ontology/identifier note (important limitation): In the retrieved evidence set, authoritative cross-references for a single umbrella concept “autosomal dominant distal hereditary motor neuronopathy” (e.g., MONDO, Orphanet, OMIM, ICD-10/ICD-11, MeSH) were not directly available. The literature instead commonly uses (i) dHMN subtype designations (e.g., dHMN-I/II/V/VII) and/or (ii) gene-labelled entities (e.g., AD-dHMN-HSPB1, AD-dHMN-GARS) (xie2020geneticandclinical pages 1-2, carroll2019inheritedneuropathies pages 11-12). A knowledge base entry typically needs to treat AD-dHMN as a genetically heterogeneous group rather than a single gene-defined disorder (zambon2023earlyonsethereditary pages 1-2, parmar2024geneticsofinherited pages 1-1).

1. Disease information (current understanding)

What is the disease?

Distal hereditary motor neuropathy (dHMN) is a clinically and genetically heterogeneous group of inherited neuromuscular disorders characterized by slowly progressive distal limb weakness and atrophy with minimal or no sensory involvement, reflecting predominant degeneration/dysfunction of motor neurons/axons (xie2020geneticandclinical pages 1-2, frasquet2021distalhereditarymotor pages 1-2, bansagi2017clinicalandgenetic pages 58-62). HMNs/dHMNs are classically described as lower motor neuron disorders with length-dependent distal weakness/atrophy, chronic denervation on needle EMG, and relatively preserved motor conduction velocities compared with demyelinating neuropathies (zambon2023earlyonsethereditary pages 1-2, zambon2023earlyonsethereditary pages 1-1).

Key concepts/definitions

• “Pure motor” neuropathy / neuronopathy: preserved sensory nerve action potentials (SNAPs) with abnormalities predominantly in motor studies and neurogenic EMG changes; mild sensory abnormalities can occur and may shift classification toward motor CMT2 (bansagi2017clinicalandgenetic pages 58-62, bansagi2017clinicalandgenetica pages 62-73).
• Continuum/overlap: There is substantial clinical and genetic overlap between dHMN and axonal CMT2, SMA-LED, juvenile ALS, and other lower motor neuron disorders; the same gene may produce different phenotypes (zambon2023earlyonsethereditary pages 1-1, bansagi2017clinicalandgenetic pages 58-62).

Common subtype nomenclature

A commonly used clinical classification partitions autosomal dominant dHMN into subtypes such as dHMN-I (childhood onset), dHMN-II (adult onset), dHMN-V (upper-limb predominance), and dHMN-VII (vocal cord palsy) (xie2020geneticandclinical pages 1-2). A gene-based nomenclature is also used (e.g., AD-dHMN-HSPB1, AD-dHMN-HSPB8, AD-dHMN-GARS, AD-dHMN-REEP1, AD-dHMN-BSCL2) (carroll2019inheritedneuropathies pages 11-12).

2. Etiology

Primary causes

Genetic etiology dominates: dHMN/HMN has autosomal dominant, autosomal recessive, and X-linked forms, with ~30 causative genes summarized in a 2023 review focused on early-onset motor neuronopathies/HMN (zambon2023earlyonsethereditary pages 1-2). In a cohort context, autosomal dominant inheritance can comprise the majority of genetically confirmed cases (e.g., 60% AD among genetically confirmed cases in one Spanish catchment cohort summary) (rossor2021broadeningthegenetic pages 1-3).

Risk factors

• Family history is a strong predictor of achieving a genetic diagnosis: one cohort summary reported 67.4% diagnostic yield in familial index cases vs 12.3% in sporadic cases (rossor2021broadeningthegenetic pages 1-3).
• Other non-genetic risk factors are not well-established in the retrieved evidence; the disorder is typically considered Mendelian with phenotype-modifying influences possible but not well-quantified in these sources (gregianin2014identificationandcharacterisation pages 27-29).

Protective factors / gene–environment interactions

No robust protective factors or gene–environment interaction data specific to AD-dHMN were identified in the retrieved evidence set.

3. Phenotypes

Core phenotype (human clinical)

Across cohort and review sources, typical features include: * Distal muscle weakness and atrophy (often length-dependent, lower-limb predominant, but can be upper-limb predominant in dHMN-V) (xie2020geneticandclinical pages 1-2, frasquet2021distalhereditarymotor pages 1-2).
Foot deformities such as pes cavus and toe clawing are commonly described (bansagi2017clinicalandgenetic pages 58-62).
Minimal/no sensory involvement by history and examination; sensory NCS are typically preserved (xie2020geneticandclinical pages 1-2, bansagi2017clinicalandgenetic pages 58-62).

Onset and progression

• Onset can be childhood to adulthood depending on subtype (xie2020geneticandclinical pages 1-2, frasquet2021distalhereditarymotor pages 1-2).
• In a Spanish cohort, the most frequent age at onset was 2–10 years (28.8%) (frasquet2021distalhereditarymotor pages 1-2).
• The course is generally slowly progressive (frasquet2021distalhereditarymotor pages 1-2, zambon2023earlyonsethereditary pages 1-2).

Electrophysiology and pathology

• HMN/dHMN are associated with chronic denervation on needle EMG and relatively preserved motor nerve conduction velocities; classification frameworks emphasize preserved sensory nerve studies (zambon2023earlyonsethereditary pages 1-2, bansagi2017clinicalandgenetic pages 58-62).
• In a regional clinic cohort, standardized nerve conduction plus EMG/motor unit potential (MUP) analysis were used for classification; authors note overlap and occasional minor sensory abnormalities (bansagi2017clinicalandgenetica pages 62-73).

Functional impact / real-world functional measurement

A dedicated observational study in adults with dHMN used objective outcomes that reflect real-world impairment: * MRI 3-point Dixon fat fraction (primary), * 3D gait analysis (kinematics/kinetics), and * isokinetic dynamometry for strength, along with clinical gait speed/endurance and other measures (NCT04193228 chunk 1, NCT04193228 chunk 2).

Suggested HPO terms (not exhaustive; ontology suggestions)

• Distal muscle weakness (HP:0002460), Muscle atrophy (HP:0003202), Foot deformity (HP:0001760), Pes cavus (HP:0001761), Claw toes (HP:0001778), Gait abnormality (HP:0001288), Lower limb muscle weakness (HP:0007340), Hand muscle weakness (HP:0002463), Motor neuropathy (HP:0003431).

Phenotype frequency/QoL limitation

The retrieved evidence contains limited per-phenotype frequency and no disease-specific QoL instrument results for AD-dHMN; most quantitative data are cohort-level (age of onset distribution, diagnostic yield, etc.) (frasquet2021distalhereditarymotor pages 1-2, rossor2021broadeningthegenetic pages 1-3).

4. Genetic / molecular information

Causal genes (with emphasis on AD-dHMN)

Autosomal dominant dHMN is genetically heterogeneous. In the available evidence, key AD-dHMN-associated gene groups include: * Small heat shock proteins / chaperones (proteostasis): HSPB1, HSPB3, HSPB8 are classified as autosomal dominant dHMN genes, and chaperone dysfunction is a major mechanistic theme (lupo2016chaperonopathiesspotlighton pages 1-2, carroll2019inheritedneuropathies pages 11-12).
Aminoacyl-tRNA synthetases (ARS): GARS1 is a canonical AD-dHMN gene (carroll2019inheritedneuropathies pages 11-12), and ARS genes were suggested as frequent causes of autosomal dominant dHMN in a Chinese family cohort (xie2020geneticandclinical pages 1-2).
ER shaping / overlap with spasticity: REEP1 is classified as an AD-dHMN gene and is associated with pyramidal signs in at least some cases (carroll2019inheritedneuropathies pages 11-12, wu2022geneticspectrumin pages 5-6).
Other AD-dHMN genes in classification frameworks: BSCL2 (Silver syndrome/CMT overlap) (carroll2019inheritedneuropathies pages 11-12).
Axonal transport pathway genes appear in HMN gene tables (e.g., DCTN1) (zambon2023earlyonsethereditary pages 1-2).

The following figure/table from a 2023 Brain review provides a consolidated view of HMN genes, inheritance patterns, and mechanistic categories, supporting the breadth of implicated biology in dHMN (zambon2023earlyonsethereditary media 8b9ba4e3, zambon2023earlyonsethereditary media 85f57af2).

Example recent (2024) dominant variant and functional consequence

A 2024 report described a novel heterozygous NARS1 variant (c.1555G>C; p.Gly519Arg) segregating with dominant dHMN, absent from population databases and supported by loss-of-function in yeast complementation assays (theuriet2024apreviouslyunreported pages 1-3). This provides a concrete example of gene/variant expansion in the AD-dHMN spectrum using WGS plus functional validation (theuriet2024apreviouslyunreported pages 1-3).

Mechanistic categories (molecular pathways; current synthesis)

A 2023 review and accompanying gene table classify HMN/dHMN genes into recurrent mechanistic themes, including unfolded protein response/proteostasis, aminoacyl-tRNA synthetase dysfunction, impaired axonal transport, and mitochondrial dysfunction/ER–mitochondria interactions (zambon2023earlyonsethereditary pages 1-2, zambon2023earlyonsethereditary media 8b9ba4e3).

Suggested GO/CL/UBERON terms (ontology suggestions)

• GO biological processes: axon transport (GO:0007411), protein folding (GO:0006457), response to unfolded protein (GO:0006986), translation (GO:0006412), mitochondrial organization (GO:0007005).
• Cell types (CL): alpha motor neuron (CL:0000578), Schwann cell (CL:0000218) (noting that dHMN is motor-predominant but nerve-supporting cells may be secondarily involved).
• Anatomy (UBERON): peripheral nerve (UBERON:0001021), spinal cord anterior horn (UBERON:0001883), skeletal muscle (UBERON:0001134).

5. Environmental information

No specific environmental, lifestyle, toxin, or infectious triggers were identified as established contributors to AD-dHMN in the retrieved evidence, consistent with a primarily genetic etiology (zambon2023earlyonsethereditary pages 1-2, frasquet2021distalhereditarymotor pages 1-2).

6. Mechanism / pathophysiology (causal chain)

Causal chain (generalized)

Pathogenic variants in genes governing proteostasis (chaperones), aminoacyl-tRNA synthetase function, axonal transport, and organelle homeostasis lead to motor neuron/peripheral motor axon dysfunction, producing length-dependent denervation and chronic reinnervation changes on EMG, culminating in distal muscle weakness/atrophy and foot/hand deformities over time (zambon2023earlyonsethereditary pages 1-2, zambon2023earlyonsethereditary pages 1-1, lupo2016chaperonopathiesspotlighton pages 1-2, theuriet2024apreviouslyunreported pages 1-3).

Upstream vs downstream

• Upstream: gene/variant-driven molecular dysfunction in chaperoning/protein quality control or translation/enzymatic ARS activity, axonal transport machinery, and mitochondrial/ER homeostasis (lupo2016chaperonopathiesspotlighton pages 1-2, theuriet2024apreviouslyunreported pages 1-3, zambon2023earlyonsethereditary pages 1-2).
• Downstream: axonal degeneration/denervation (electrophysiologic neurogenic changes), muscle atrophy, gait impairment, orthopedic deformities (zambon2023earlyonsethereditary pages 1-2, bansagi2017clinicalandgenetic pages 58-62, NCT04193228 chunk 1).

7. Anatomical structures affected

Primary: peripheral motor nerves/axons and motor neuron cell bodies (lower motor neuron system) (zambon2023earlyonsethereditary pages 1-2, zambon2023earlyonsethereditary pages 1-1).
Secondary: distal skeletal muscles (especially intrinsic foot muscles/peroneal compartment; can include hand muscles in dHMN-V) and related musculoskeletal structures through chronic weakness and imbalance (bansagi2017clinicalandgenetic pages 58-62, xie2020geneticandclinical pages 1-2).

8. Temporal development

• Onset: childhood through adulthood depending on subtype; common childhood onset reported in cohorts (e.g., 2–10 years most frequent onset in one cohort) (frasquet2021distalhereditarymotor pages 1-2).
• Progression: typically slow and chronic; adult patients in one NARS1 family remained ambulatory, suggesting relatively slowly progressive disease in that genotype (theuriet2024apreviouslyunreported pages 1-3).

9. Inheritance and population

Inheritance

By definition here, autosomal dominant dHMN includes families with heterozygous segregating variants; however, dHMN overall includes AD/AR/X-linked cases (zambon2023earlyonsethereditary pages 1-2, xie2020geneticandclinical pages 1-2). In a North-East England clinic cohort, 16/40 dHMN families were dominant, with many additional isolated cases (bansagi2017clinicalandgenetic pages 62-73).

Epidemiology (recently summarized quantitative metrics)

Prevalence estimates across studies/reviews converge in the range of ~2 per 100,000 (though methodology and case ascertainment differ): * Pooled HMN prevalence estimate: 2.14/100,000 (zambon2023earlyonsethereditary pages 1-2).
Minimum prevalence in a Spanish dHMN cohort: 2.3/100,000 (frasquet2021distalhereditarymotor pages 1-2).
North-East England dHMN prevalence: 2.14/100,000 (95% CI 1.62–2.66) (bansagi2017clinicalandgenetic pages 62-73).
A Spanish catchment cohort summary reported prevalence ~1 in 50,000* (equivalent to 2/100,000) (rossor2021broadeningthegenetic pages 1-3).

A comparative summary of key prevalence, AD proportion, and diagnostic-yield statistics is provided in the table below.

Table: This table compiles explicit epidemiology and diagnostic-yield statistics for distal hereditary motor neuropathy across key cohort and review sources, highlighting autosomal dominant proportions where reported. It is useful for comparing prevalence estimates, inheritance mix, and genetic testing performance across settings.

10. Diagnostics

Core diagnostic approach (real-world)

1. Clinical pattern recognition: distal motor-predominant weakness/atrophy, often with foot deformities and preserved sensation (bansagi2017clinicalandgenetic pages 58-62, frasquet2021distalhereditarymotor pages 1-2).
2. Electrophysiology: NCS/EMG to demonstrate predominantly motor involvement and chronic denervation, and to exclude demyelinating neuropathy (zambon2023earlyonsethereditary pages 1-2, bansagi2017clinicalandgenetica pages 62-73).
3. Exclude acquired mimics via laboratory/metabolic and other testing (in at least one regional cohort, extensive investigations including imaging/biopsy were used to exclude acquired neuropathies) (bansagi2017clinicalandgenetic pages 58-62).
4. Genetic testing: massively parallel sequencing using targeted gene panels and/or WES/WGS; diagnostic yield varies by family history and testing approach (rossor2021broadeningthegenetic pages 1-3, bansagi2017clinicalandgenetica pages 76-82, theuriet2024apreviouslyunreported pages 1-3).

Genetic testing strategy (current and emerging)

• Panel/WES/WGS: A regional cohort reported modality-associated yields (targeted testing 4.7%, IPN panel 26%, WES 45%), and emphasized pedigree-level analysis to avoid ascertainment bias (bansagi2017clinicalandgenetic pages 76-82).
• Segregation testing is critical: in one cohort, segregation reclassified ~54% of VUS to likely benign, underscoring the need for family studies rather than relying solely on in silico predictions (frasquet2021distalhereditarymotor pages 7-8).
• Emerging variant classes: 2024 expert review emphasizes that structural variants and short tandem repeat expansions contribute to inherited peripheral neuropathy “missing heritability” and that long-read/optical mapping and improved informatics may improve diagnosis (parmar2024geneticsofinherited pages 1-2, parmar2024geneticsofinherited pages 5-6).

Differential diagnosis (high-level)

Given overlap, key clinical differentials include axonal CMT2 (motor-predominant forms), SMA-LED, juvenile ALS and other lower motor neuron disorders (zambon2023earlyonsethereditary pages 1-1, zambon2023earlyonsethereditary pages 1-2).

11. Outcome / prognosis

The disease is generally slowly progressive; subtype/genotype influences severity and whether additional signs appear (e.g., pyramidal signs in REEP1-labelled AD-dHMN) (frasquet2021distalhereditarymotor pages 1-2, carroll2019inheritedneuropathies pages 11-12, wu2022geneticspectrumin pages 5-6). Robust survival/mortality statistics are not provided in the retrieved evidence and are likely less relevant than in ALS-spectrum disorders.

12. Treatment

Current standard of care (current evidence in retrieved set)

For inherited neuropathies broadly, management remains largely symptomatic/supportive, with limited disease-modifying options for most genetic neuropathies (hustinx2023noveltherapeuticapproaches pages 1-2). In the AD-dHMN literature retrieved here, specific disease-modifying pharmacotherapies were not established.

Rehabilitation and assistive devices (real-world implementation)

A completed observational study in dHMN evaluated: * bilateral carbon-fibre ankle–foot orthoses (AFOs), and
a 16-week home-based resistance program* with remote supervision and app monitoring, alongside quantitative MRI and gait outcomes (NCT04193228 chunk 1). This demonstrates that structured rehabilitation interventions and orthotic management are being implemented and studied with objective endpoints in dHMN.

Therapeutic research landscape and outcome measurement (2023–2024 perspective)

A 2023 systematic review of emerging therapies in inherited neuropathies identified 28 studies with neuropathy outcomes and concluded that neuropathy symptoms/biomarkers were assessed in only a minority of trials; it recommended objective and consistent methods such as wearables, motor unit indexes, MRI/sonography, blood biomarkers, and standardized NCS endpoints to improve comparability (hustinx2023noveltherapeuticapproaches pages 1-2).

Suggested MAXO terms (ontology suggestions)

• Ankle-foot orthosis use (MAXO:0000808; if not available, “orthotic device therapy”), Physical therapy (MAXO:0000011), Resistance training/exercise therapy (MAXO:0000127), Genetic counseling (MAXO:0000071).

13. Prevention

No primary prevention exists for Mendelian AD-dHMN beyond family planning and risk assessment. Secondary prevention includes early recognition and genetic diagnosis to shorten the diagnostic odyssey and optimize supportive interventions (parmar2024geneticsofinherited pages 1-2).

14. Other species / natural disease

No naturally occurring non-human disease analogs were identified in the retrieved evidence set.

15. Model organisms and experimental systems (research direction)

A 2024 review on inherited peripheral neuropathy genetics highlights the need for functional evidence and recommends animal models (e.g., C. elegans and rodents) for variant validation and mechanistic work, while noting barriers to scalability and cost for high-throughput functional assays (parmar2024geneticsofinherited pages 5-6). A 2024 dominant dHMN report used yeast complementation assays as functional validation for an ARS gene variant (NARS1), reflecting increasing use of orthogonal functional systems to support pathogenicity claims (theuriet2024apreviouslyunreported pages 1-3).

Key statistics (selected)

• Prevalence estimates for HMN/dHMN around ~2 per 100,000 across multiple cohorts/reviews (bansagi2017clinicalandgenetic pages 62-73, frasquet2021distalhereditarymotor pages 1-2, zambon2023earlyonsethereditary pages 1-2).
• Autosomal dominant constitutes a substantial fraction of genetically confirmed cases in at least one catchment cohort (e.g., 60% AD among genetically confirmed cases in Valencia) (rossor2021broadeningthegenetic pages 1-3).
• Diagnostic yield is strongly influenced by family history (67.4% familial vs 12.3% sporadic in one cohort summary) (rossor2021broadeningthegenetic pages 1-3).
• Genetic diagnostic yield for a “pure HMN phenotype” reported as ~32.5% in a 2023 review (zambon2023earlyonsethereditary pages 1-2).

Evidence-backed gene summary (AD-dHMN focus)

Table: This table summarizes genes with available evidence for autosomal dominant distal hereditary motor neuropathy, highlighting example variants, mechanism classes, and phenotype notes. It is useful for quickly linking genotype, disease mechanism, and the strength or limitations of the available evidence.

Evidence and reporting limitations (important for knowledge base curation)

1. Identifiers/ontologies: direct MONDO/OMIM/Orphanet/ICD/MeSH identifiers were not retrieved in the current tool context; the knowledge base should model AD-dHMN as a group with gene-labelled subentities (carroll2019inheritedneuropathies pages 11-12, zambon2023earlyonsethereditary pages 1-2).
2. Per-phenotype frequencies and QoL: sparse in retrieved evidence; most available statistics are at cohort/diagnostic-yield level (frasquet2021distalhereditarymotor pages 1-2, rossor2021broadeningthegenetic pages 1-3).
3. Direct abstract quotations: while several records include abstracts, the evidence extraction available here did not preserve short verbatim abstract quotes for most key claims; key statements are therefore paraphrased but tightly linked to the cited primary sources.

Key references (publication date; URL)

• Zambon AA et al. Brain. 2023 (online/print Nov 2023). https://doi.org/10.1093/brain/awac452 (zambon2023earlyonsethereditary pages 1-2, zambon2023earlyonsethereditary media 8b9ba4e3)
• Theuriet J et al. J Peripher Nerv Syst. May 2024. https://doi.org/10.1111/jns.12635 (theuriet2024apreviouslyunreported pages 1-3)
• Parmar JM et al. J Neurol Neurosurg Psychiatry. May 2024. https://doi.org/10.1136/jnnp-2024-333436 (parmar2024geneticsofinherited pages 1-2, parmar2024geneticsofinherited pages 5-6)
• Hustinx M et al. Pharmaceutics. May 2023. https://doi.org/10.3390/pharmaceutics15061626 (hustinx2023noveltherapeuticapproaches pages 1-2)
• Frasquet M et al. Eur J Neurol. Jan 2021. https://doi.org/10.1111/ene.14700 (frasquet2021distalhereditarymotor pages 1-2, frasquet2021distalhereditarymotor pages 7-8)
• Rossor AM. Eur J Neurol. Feb 2021. https://doi.org/10.1111/ene.14734 (rossor2021broadeningthegenetic pages 1-3)
• ClinicalTrials.gov: NCT04193228 (UCLH). Posted/updated within registry record; protocol includes MRI Dixon fat fraction and 3D gait analysis. https://clinicaltrials.gov/study/NCT04193228 (NCT04193228 chunk 1, NCT04193228 chunk 2)

References

1. (xie2020geneticandclinical pages 1-2): Yongzhi Xie, Zhiqiang Lin, Pukar Singh Pakhrin, Xiaobo Li, Binghao Wang, Lei Liu, Shunxiang Huang, Huadong Zhao, Wanqian Cao, Zhengmao Hu, Jifeng Guo, Lu Shen, Beisha Tang, and Ruxu Zhang. Genetic and clinical features in 24 chinese distal hereditary motor neuropathy families. Frontiers in Neurology, Dec 2020. URL: https://doi.org/10.3389/fneur.2020.603003, doi:10.3389/fneur.2020.603003. This article has 13 citations and is from a peer-reviewed journal.

2. (frasquet2021distalhereditarymotor pages 1-2): Marina Frasquet, Ricard Rojas‐García, Herminia Argente‐Escrig, Juan Francisco Vázquez‐Costa, Nuria Muelas, Juan Jesús Vílchez, Rafael Sivera, Elvira Millet, Marisa Barreiro, Jordi Díaz‐Manera, Janina Turon‐Sans, Elena Cortés‐Vicente, Luis Querol, Laura Ramírez‐Jiménez, Dolores Martínez‐Rubio, Ana Sánchez‐Monteagudo, Carmen Espinós, Teresa Sevilla, and Vincenzo Lupo. Distal hereditary motor neuropathies: mutation spectrum and genotype–phenotype correlation. Jan 2021. URL: https://doi.org/10.1111/ene.14700, doi:10.1111/ene.14700. This article has 75 citations and is from a domain leading peer-reviewed journal.

3. (bansagi2017clinicalandgenetic pages 58-62): BK Bansagi. Clinical and genetic characterisation of hereditary motor neuropathies. Unknown journal, 2017.

4. (zambon2023earlyonsethereditary pages 1-2): Alberto A Zambon, Veronica Pini, Luca Bosco, Yuri M Falzone, Pinki Munot, Francesco Muntoni, and Stefano C Previtali. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain, 146:806-822, Nov 2023. URL: https://doi.org/10.1093/brain/awac452, doi:10.1093/brain/awac452. This article has 36 citations and is from a highest quality peer-reviewed journal.

5. (zambon2023earlyonsethereditary pages 1-1): Alberto A Zambon, Veronica Pini, Luca Bosco, Yuri M Falzone, Pinki Munot, Francesco Muntoni, and Stefano C Previtali. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain, 146:806-822, Nov 2023. URL: https://doi.org/10.1093/brain/awac452, doi:10.1093/brain/awac452. This article has 36 citations and is from a highest quality peer-reviewed journal.

6. (carroll2019inheritedneuropathies pages 11-12): Antonia S. Carroll, Joshua Burns, Garth Nicholson, Matthew C. Kiernan, and Steve Vucic. Inherited neuropathies. Seminars in Neurology, 39:620-639, Oct 2019. URL: https://doi.org/10.1055/s-0039-1693006, doi:10.1055/s-0039-1693006. This article has 21 citations and is from a peer-reviewed journal.

7. (parmar2024geneticsofinherited pages 1-1): Jevin M. Parmar, Nigel G. Laing, Marina L. Kennerson, and Gianina Ravenscroft. Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards. Journal of Neurology, Neurosurgery & Psychiatry, 95:992-1001, May 2024. URL: https://doi.org/10.1136/jnnp-2024-333436, doi:10.1136/jnnp-2024-333436. This article has 21 citations.

8. (bansagi2017clinicalandgenetica pages 62-73): BK Bansagi. Clinical and genetic characterisation of hereditary motor neuropathies. Unknown journal, 2017.

9. (rossor2021broadeningthegenetic pages 1-3): Alexander M. Rossor. Broadening the genetic spectrum of distal hereditary motor neuropathy. European Journal of Neurology, 28:1104-1105, Feb 2021. URL: https://doi.org/10.1111/ene.14734, doi:10.1111/ene.14734. This article has 1 citations and is from a domain leading peer-reviewed journal.

10. (gregianin2014identificationandcharacterisation pages 27-29): E Gregianin. Identification and characterisation of novel genes in motor neuron disorders. Unknown journal, 2014.

11. (NCT04193228 chunk 1): Gita Ramdharry. Muscle Structure, Function and Gait in dHMN. University College London Hospitals. 2021. ClinicalTrials.gov Identifier: NCT04193228

12. (NCT04193228 chunk 2): Gita Ramdharry. Muscle Structure, Function and Gait in dHMN. University College London Hospitals. 2021. ClinicalTrials.gov Identifier: NCT04193228

13. (lupo2016chaperonopathiesspotlighton pages 1-2): Vincenzo Lupo, Carmen Aguado, Erwin Knecht, and Carmen Espinós. Chaperonopathies: spotlight on hereditary motor neuropathies. Frontiers in Molecular Biosciences, Dec 2016. URL: https://doi.org/10.3389/fmolb.2016.00081, doi:10.3389/fmolb.2016.00081. This article has 39 citations.

14. (wu2022geneticspectrumin pages 5-6): Chengsi Wu, Haijie Xiang, Ran Chen, Yilei Zheng, Min Zhu, Shuyun Chen, Yanyan Yu, Yun Peng, Yaqing Yu, Jianwen Deng, Meihong Zhou, and Daojun Hong. Genetic spectrum in a cohort of patients with distal hereditary motor neuropathy. Annals of Clinical and Translational Neurology, 9:633-643, Mar 2022. URL: https://doi.org/10.1002/acn3.51543, doi:10.1002/acn3.51543. This article has 21 citations and is from a peer-reviewed journal.

15. (zambon2023earlyonsethereditary media 8b9ba4e3): Alberto A Zambon, Veronica Pini, Luca Bosco, Yuri M Falzone, Pinki Munot, Francesco Muntoni, and Stefano C Previtali. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain, 146:806-822, Nov 2023. URL: https://doi.org/10.1093/brain/awac452, doi:10.1093/brain/awac452. This article has 36 citations and is from a highest quality peer-reviewed journal.

16. (zambon2023earlyonsethereditary media 85f57af2): Alberto A Zambon, Veronica Pini, Luca Bosco, Yuri M Falzone, Pinki Munot, Francesco Muntoni, and Stefano C Previtali. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain, 146:806-822, Nov 2023. URL: https://doi.org/10.1093/brain/awac452, doi:10.1093/brain/awac452. This article has 36 citations and is from a highest quality peer-reviewed journal.

17. (theuriet2024apreviouslyunreported pages 1-3): Julian Theuriet, Sheila Marte, Arnaud Isapof, Alix de Becdelièvre, Marina Konyukh, Stephanie M. Laureano‐Figueroa, Philippe Latour, Isabelle Quadrio, Thierry Maisonobe, Anthony Antonellis, and Tanya Stojkovic. A previously unreported nars1 variant causes dominant distal hereditary motor neuropathy in a french family. Journal of the peripheral nervous system : JPNS, 29:275-278, May 2024. URL: https://doi.org/10.1111/jns.12635, doi:10.1111/jns.12635. This article has 3 citations.

18. (bansagi2017clinicalandgenetic pages 62-73): BK Bansagi. Clinical and genetic characterisation of hereditary motor neuropathies. Unknown journal, 2017.

19. (frasquet2021distalhereditarymotor pages 7-8): Marina Frasquet, Ricard Rojas‐García, Herminia Argente‐Escrig, Juan Francisco Vázquez‐Costa, Nuria Muelas, Juan Jesús Vílchez, Rafael Sivera, Elvira Millet, Marisa Barreiro, Jordi Díaz‐Manera, Janina Turon‐Sans, Elena Cortés‐Vicente, Luis Querol, Laura Ramírez‐Jiménez, Dolores Martínez‐Rubio, Ana Sánchez‐Monteagudo, Carmen Espinós, Teresa Sevilla, and Vincenzo Lupo. Distal hereditary motor neuropathies: mutation spectrum and genotype–phenotype correlation. Jan 2021. URL: https://doi.org/10.1111/ene.14700, doi:10.1111/ene.14700. This article has 75 citations and is from a domain leading peer-reviewed journal.

20. (bansagi2017clinicalandgenetica pages 76-82): BK Bansagi. Clinical and genetic characterisation of hereditary motor neuropathies. Unknown journal, 2017.

21. (bansagi2017clinicalandgenetic pages 76-82): BK Bansagi. Clinical and genetic characterisation of hereditary motor neuropathies. Unknown journal, 2017.

22. (parmar2024geneticsofinherited pages 1-2): Jevin M. Parmar, Nigel G. Laing, Marina L. Kennerson, and Gianina Ravenscroft. Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards. Journal of Neurology, Neurosurgery & Psychiatry, 95:992-1001, May 2024. URL: https://doi.org/10.1136/jnnp-2024-333436, doi:10.1136/jnnp-2024-333436. This article has 21 citations.

23. (parmar2024geneticsofinherited pages 5-6): Jevin M. Parmar, Nigel G. Laing, Marina L. Kennerson, and Gianina Ravenscroft. Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards. Journal of Neurology, Neurosurgery & Psychiatry, 95:992-1001, May 2024. URL: https://doi.org/10.1136/jnnp-2024-333436, doi:10.1136/jnnp-2024-333436. This article has 21 citations.

24. (hustinx2023noveltherapeuticapproaches pages 1-2): Manon Hustinx, Ann-Marie Shorrocks, and Laurent Servais. Novel therapeutic approaches in inherited neuropathies: a systematic review. Pharmaceutics, 15:1626, May 2023. URL: https://doi.org/10.3390/pharmaceutics15061626, doi:10.3390/pharmaceutics15061626. This article has 6 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01